Each ingredient in Nerve Alive has an independent body of published research. Below is a plain-English walkthrough of what that literature actually found — and what it did not claim.
Every reference below links to the original PubMed or NIH record. We do not paraphrase study conclusions beyond what the published data supports.
One of the most referenced ALA trials enrolled adults with distal symmetric polyneuropathy and measured changes in the validated Total Symptom Score (TSS) — a composite of burning pain, stabbing sensations, tingling, and numbness. Participants receiving 600 mg oral ALA daily for five weeks showed statistically significant TSS improvements compared to the placebo arm. The 600 mg/day dose used in this trial matches the dose printed on Nerve Alive's Supplement Facts panel.
PubMed: 16936168 →This randomized trial evaluated benfotiamine against placebo in adults with symptomatic diabetic polyneuropathy over six weeks. The treatment group demonstrated meaningful reductions in neuropathic symptom composite scores compared to control. Researchers attributed the benefit to benfotiamine's activation of transketolase and downstream reduction of AGE (advanced glycation end-product) accumulation around peripheral nerve tissue — a mechanism not shared by standard water-soluble thiamine.
PubMed: 18463968 →A clinical evaluation of methylcobalamin supplementation in adults with peripheral neuropathy of diabetic origin tracked both subjective symptom scores and objective nerve conduction measurements. The methylated B12 form — used at doses consistent with Nerve Alive's label — supported improvements in nerve conduction velocity parameters and was associated with reduced patient-reported neuropathic symptoms over the study period. Importantly, the study used methylcobalamin rather than cyanocobalamin, the cheaper synthetic form prevalent in generic supplements.
PubMed: 16330422 →A pooled analysis combining data from two large parallel trials evaluated ALC at 1,000 mg three times daily in patients with symptomatic diabetic neuropathy over 52 weeks. Significant reductions in pain scores on the Visual Analog Scale and improvements in nerve fiber regeneration density (measured by sural nerve biopsy) were observed in the ALC group relative to placebo. The regeneration density finding is notable — it suggests a structural, not merely symptomatic, effect on peripheral nerve tissue.
PubMed: 15735218 →A meta-analysis pooling data from 12 clinical studies and 787 participants examined PEA across multiple chronic pain and neuropathic pain conditions. The pooled analysis found consistent reductions in pain scores across study populations and etiologies, with a favorable tolerability profile and no significant adverse events reported across the included trials. PEA's proposed mechanism — modulation of mast cell and glial cell activity at sites of nerve irritation — is distinct from the mechanisms of the other four ingredients, making it a complementary addition to the formula.
PubMed: 23526762 →The studies above were conducted on the individual ingredients — not on the Nerve Alive formulation itself. Summarised findings here reflect published data for each nutrient in isolation at doses comparable to those in the formula. They should not be interpreted as a claim that Nerve Alive will replicate the outcomes reported in these trials. Dietary supplements are not drugs. Outcomes vary significantly based on the individual's health status, severity of symptoms, consistency of use, and other factors.